STOCKHOLM, Sweden, 17th March 2025 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that all patients in the ongoing Phase III study for the drug candidate AKP02G2 have been randomized. Lipidor now expects study results in the last week of May 2025. The main purpose of the clinical study is to […]
STOCKHOLM, Sweden, 28th February 2025 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its year-end report for the period January – December 2024. The report is available on the company's website lipidor.se and in the attached pdf. To read the year-end report (in Swedish) click here: https://lipidor.se/investors/financial-reports/ Summary During the year, […]
STOCKHOLM, Sweden, 21st January 2025 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that half of the patients in the ongoing Phase III study for the drug candidate AKP02G2 have been randomized in the clinical study. The refined forecast now shows results in April 2025. The main purpose of the clinical […]
STOCKHOLM, Sweden, 3rd December 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today presents its Nomination Committee, which shall have four members, in accordance with the applicable instructions resolved by the Annual General Meeting 2020. The three largest shareholders who are registered with Euroclear Sweden AB on the last of September before […]
STOCKHOLM, Sweden, 20 November 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today provides an update on the business from CEO Ola Holmlund, also announcing a company presentation to take place during Aktiespararna’s National Event in Stockholm next week. Statement from the CEO Due to the fact that Lipidor has switched to […]
STOCKHOLM, Sweden, 24 September 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the first patient has been enrolled in the Phase III clinical study with AKP02G2. The drug candidate AKP02G2 combines calcipotriol and betamethasone and is based on Lipidor's patented AKVANO® technology. The goal of AKP02G2 is to offer […]
STOCKHOLM, Sweden, 28 August 2024 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its interim report for the period January – June 2024. The report is available on the company's website lipidor.se and in the attached pdf. To read the quarterly report (in Swedish) click here: https://lipidor.se/investors/financial-reports/ Summary of second quarter […]
STOCKHOLM, Sweden, 20th August 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that the clinical trial material for the company's upcoming clinical Phase III study with the drug candidate AKP02G2 is ready and has been shipped to our CRO. It marks a critical milestone in the project plan and creates […]
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION FURTHER REQUIRES PROSPECTUS, REGISTRATION, OR OTHER ACTIONS OTHER THAN THOSE UNDER SWEDISH LAW, ARE PROHIBITED, OR OTHERWISE […]
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION FURTHER REQUIRES PROSPECTUS, REGISTRATION, OR OTHER ACTIONS OTHER THAN THOSE UNDER SWEDISH LAW, ARE PROHIBITED, OR OTHERWISE CONTRARY […]